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Background: Paroxetine, a selective serotonin reuptake inhibitor for counteracting depression, has been recently
suggested as having a role in prevention of dopaminergic neuronal degeneration in substantia nigra, a hallmark of
Parkinson’s disease (PD). The pathogenesis of this type of neurological disorders often involves the activation of
microglia and associated inflammatory processes. Thus in this study we aimed to understand the role of paroxetine
in microglia activation and to elucidate the underlying mechanism(s).
Methods: BV2 and primary microglial cells were pretreated with paroxetine and stimulated with lipopolysaccharide
(LPS). Cells were assessed for the responses of pro-inflammatory mediator and cytokines, and the related signaling
pathways were evaluated and analyzed in BV2 cells.
Results: Paroxetine significantly inhibited LPS-induced production of nitric oxide (NO) and pro-inflammatory cytokines
such as TNF-α and IL-1β. Further analysis showed inducible nitric oxide synthase (iNOS) and mRNA expression of TNF-α
and IL-1β were attenuated by paroxetine pretreatment. Analyses in signaling pathways demonstrated that paroxetine led
to suppression of LPS-induced JNK1/2 activation and baseline ERK1/2 activity, but had little effect on the activation of p38
and p65/NF-κB. Interference with specific inhibitors revealed that paroxetine-mediated suppression of NO production was
via JNK1/2 pathway while the cytokine suppression was via both JNK1/2 and ERK1/2 pathways. Furthermore, conditioned
media culture showed that paroxetine suppressed the microglia-mediated neurotoxicity.
Conclusions: Paroxetine inhibits LPS-stimulated microglia activation through collective regulation of JNK1/2 and ERK1/2
signaling. Our results indicate a potential role of paroxetine in neuroprotection via its anti-neuroinflammatory effect
besides targeting for depression.
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Parkinson’s disease (PD) is the second most common
neurodegenerative disease characterized by a dramatic loss
of dopaminergic neurons in substantia nigra. Although the
etiology of PD and the underlying mechanisms for disease
development remain incompletely understood, increasing
evidence has suggested that inflammatory processes* Correspondence: zhangxiong98@gmail.com; jianhong.zhu@gmail.com
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unless otherwise stated.play a key role in the pathogenesis of PD [1-3]. Microglia
are the resident macrophages of the central nervous
system and act as the prime effector cells in mediating
neuroinflammation [4,5]. It has been suggested that
inflammatory mediators such as nitric oxide (NO), TNF-α,
and IL-1β derived from microglia are involving in the
progression of neuronal cell death in PD [6,7]. Indeed,
lipopolysaccharide (LPS) as an inflammation elicitor has
often been used to generate phenotypes of PD in animals
[8,9]. Therefore, modulation of microglial activation and its
production of pro-inflammatory mediators and cytokines
would be a promising strategy to alleviate the progression
of PD.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain




















Figure 1 Cell viability of BV2 cells treated with paroxetine. Cells
were treated with 0, 0.1, 0.2, 1, 5 or 10 μM of paroxetine for 24 hours.
Cell viability was expressed as percentage of the control (0 μM), which
was set as 100%. Values are means ± SE of three independent
experiments. *P < 0.05 versus the control; PAR, paroxetine.
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http://www.jneuroinflammation.com/content/11/1/47Paroxetine, a selective serotonin reuptake inhibitor, is
often used as a first-line treatment in the treatment of
depression because of its fewer side effects and lower
toxicity compared with other antidepressants [10].
Considering depression is one of the most common
non-motor symptoms of PD, occurring in approximately
35% of these patients [11], paroxetine has been clinically
tested as a safe and effective drug to treat PD-associated
depression [12,13]. Interestingly, a recent study disclosed
that paroxetine can prevent the degeneration of nigrostria-
tal dopaminergic neurons by inhibiting glial activation and
brain inflammation in an MPTP-induced animal model of
PD [14], suggesting that paroxetine may also contribute
to the alleviation of PD progression by inhibiting neuroin-
flammation, whereas the associating signaling mechanisms
remain elusive. In the current study we devoted ourselves
to further define the anti-inflammatory effect of paroxetine
on microglia activation and, in particular, to dissect the
underlying molecular mechanism(s).
Materials and methods
Reagents and cell culture
The BV2 microglial cells (gift of Dr. Zhu CQ, Fudan
University) and SH-SY5Y cells (Cell Bank of Chinese
Academy of Sciences, Shanghai, China) were grown in
DMEM (Invitrogen, Grand Island, NY, USA) supplemented
with 10% FBS (Invitrogen, Grand Island, NY, USA),
penicillin (100 U/ml)/streptomycin (100 μg/ml) (Solarbio
Science and Technology, Beijing, China). Cells were
maintained in a humidified incubator at 37°C with 5%
CO2. LPS and paroxetine were purchased from Sigma
(St. Louis, MO, USA). BV2 cells were seeded at a density
of 1 × 105 cells/well in a 12-well plate, and allowed to
settle at 37°C for 24 hours followed by serum starvation
overnight. Cells were pretreated with paroxetine, SP600125
(Beyotime, Shanghai, China) or U0126 (Cell Signaling,
Boston, MA, USA) for 30 minutes before LPS (100 ng/ml)
stimulation.Primary microglial cells were prepared as previously
described with slight modifications [15]. Briefly, cerebral
cortices were isolated from Institute of Cancer Research
(ICR) mice at postnatal day one to two. Meninges and
blood vessels were removed completely in cold Hank’s
buffered saline. Cortices were then minced with sterile
scissors and digested with 0.25% Trypsin-EDTA solution
(Invitrogen, Grand Island, NY, USA) for 20 minutes
at 37°C. Trypsinization was stopped by adding an
equal volume of culture medium, that is, DMEM-F-12
nutrient mixture (Invitrogen, Grand Island, NY, USA)
supplemented with 10% FBS and penicillin (100 U/ml)/
streptomycin (100 μg/ml), followed by an addition of
deoxyribonuclease I (65 unit/ml of final concentration;
Solarbio Science and Technology, Beijing, China). The
dissociated cells were pelleted at 200 g for five minutes,
resuspended in culture medium, repeatedly pipetted and
then passed through a 100 μm pore mesh. Cells were
seeded on poly-L-lysine (1 mg/mL)-coated flasks and
cultured at 37°C with 5% CO2. The medium was replaced
every four to five days after seeding. After 12 to 14 days,
microglial cells were isolated from mixed glial cultures by
vigorous shaking for four hours at 200 rpm at 37°C. Cells
were then pelleted, resuspended in mixed glial-conditioned
medium and seeded into 24-well plates at a density
of 5 × 105 cells/well. Cells were washed with PBS and
replaced with fresh culture medium after one hour to
remove non-adherent cells. After 24 hours of culture,
the cells were starved overnight and proceeded to
treatments. The purity of primary microglial cells in the
culture was assessed with staining of Iba-1 antibody
(Wako, Osaka, Japan) and Hoechst 33258 (Beyotime,
Shanghai, China).
Cell viability
Cell viability was determined by the tetrazolium salt
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide
(MTT; Sigma, St. Louis, MO, USA) assay [16]. BV2 and
primary microglial cells were initially seeded into 96-well
plates at a density of 1 × 104 cells/well and 5 × 104 cells/well,
respectively. Following treatment, MTT (5 mg/ml in PBS)
was added to each well and incubated at 37°C for four
hours. The resulting formazan crystals were dissolved in
dimethylsulfoxide (DMSO). The optical density was
measured at 570 nm, and results are expressed as a
percentage of surviving cells compared with the control.
Determination of cytokine production
Medium TNF-α and IL-1β were measured using ELISA kits
purchased from R&D Systems (Minneapolis, MN, USA)
following the manufacturer’s instruction. Briefly, standards
and samples were added to a 96-well ELISA plate precoated
with biotinylated anti-TNF-α or anti-IL-1β antibody. After








































































































Figure 2 Paroxetine attenuates lipopolysaccharide (LPS)-induced TNF-α and IL-1β in BV2 cells. (A) Concentrations of TNF-α and IL-1β in culture
media. BV2 cells were pretreated with paroxetine at 0, 0.1, 0.2, 1 or 5 μM for 30 minutes and then stimulated with LPS at 100 ng/ml for 24 hours. *P< 0.05
versus treated with LPS alone. (B) The mRNA expression of TNF-α and IL-1β. BV2 cells were pretreated with 5 μM paroxetine for 30 minutes followed by
LPS treatment at 100 ng/mL for six hours. The mRNA levels of each cytokine were quantified and normalized with their respective β-actin. Each value was
then expressed relative to the one treated with LPS alone, which was set as 100. *P< 0.05; values are means ± SE of three independent experiments. PAR,
paroxetine; LPS, lipopolysaccharide.
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to the wells and incubated for two hours. The wells were
then washed four times and filled with the substrate
solution for an incubation of 30 minutes. The reaction was
terminated by the stop solution. Absorbance was read at
450 nm in a microplate reader. The concentration of each
sample was calculated from the standard curve prepared
using the cytokine standards.
NO release assay
Medium nitrite was measured as an indicator of NO
production [17]. In brief, 50 μl of supernatant was mixed
with an equal volume of Griess reagent I, followed by an
addition of another 50 μl of Griess reagent II (Beyotime,
Shanghai, China) at room temperature. Absorbance
was immediately measured at 540 nm. The samples were
assayed in triplicate, and the concentration of each samplewas calculated from a standard curve generated using
sodium nitrite.
RNA isolation and RT-PCR
Total RNA was extracted using TRIZOL reagent (Invitrogen,
Grand Island, NY, USA), and reverse-transcribed to cDNA
using a kit from Tiangen (Tianjin, China). TNF-α and IL-1β
genes were amplified using the following primer pairs:





reaction was conducted as follows: an initial denaturation
at 94°C for three minutes, 32 cycles of 94°C for 30 seconds,
48°C (IL-1β) or 60°C (TNF-α and β-actin) for 45 seconds,



















































Figure 3 Paroxetine inhibits lipopolysaccharide (LPS)-induced
nitric oxide (NO) production and inducible nitric oxide synthase
(iNOS) expression in BV2 cells. Cells were pretreated with paroxetine
at 0, 0.1, 0.2, 1 or 5 μM for 30 min and then stimulated with LPS at
100 ng/ml for 24 hours. (A) Measurement of nitrite in culture media as
an indicator of NO production. (B) Western blot analysis of iNOS
expression. The protein levels were quantified and normalized with
their respective β-actin levels. Each value was then expressed relative
to the one treated with LPS alone, which was set as 100. *P < 0.05
versus treated with LPS alone. Values are means ± SE of three
independent experiments. PAR, paroxetine; LPS, lipopolysaccharide;
NO, nitric oxide; iNOS, inducible nitric oxide synthase.
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gel containing ethidium bromide, and were visualized
under a gel imaging system.
Western blotting analysis
Cells were lysed in sample buffer containing 60 mM
Tris-HCl, pH 6.8, 5% glycerol and 2% SDS. Cell lysates
were then boiled for five minutes and protein concentration
was measured using a BCA kit purchased from Beyotime
(Shanghai, China). Samples were subject to Western blot
analysis as previously described [18]. In brief, equal amount
of proteins was loaded and separated on a 7 or 10% SDS-
PAGE gel and transferred to a PVDF membrane, whichwas then blocked with 5% milk for one hour at room
temperature. The membrane was incubated overnight at 4°C
with primary antibody followed by a secondary horse-
radish peroxidase-conjugated antibody for one hour at
room temperature. Blots were developed using enhanced
chemiluminescence (LumiGLO® Reagent and Peroxide,
Cell Signaling, Boston, MA, USA) according to the
manufacturer’s protocol. Primary antibodies against
iNOS, p-JNK1/2, p-p38, p-ERK1/2, p-p65, JNK1/2, p38,
ERK1/2, p65, and β-actin, and secondary anti-rabbit or
anti-mouse antibody were all purchased from Cell
Signaling (Boston, MA, USA).
Microglia conditioned media
Human SH-SY5Y cells were plated in 96-well plates at a
density of 1 × 104 cells per well and allowed to settle for
24 hours at 37°C before replacement with conditioned
media. Culture media of BV2 cells with different treatments
were collected as conditioned media and clarified by
centrifugation at 20,000 × g for five minutes to remove
cellular debris. The media were then transferred onto
SH-SY5Ycells. The viability of SH-SY5Y cells was measured
using the MTT assay as described above after 24 hours
incubation.
Statistical analysis
Data were performed by a one-way analysis of variance
(ANOVA) with Dunnett’s test using the statistical package
of Predictive Analytics Software 18.0 (PASW, version
18.0) for windows. Difference was considered significant
when P < 0.05.
Results
Paroxetine reduces pro-inflammatory cytokines in LPS-
stimulated BV2 cells
Prior to study the impact of paroxetine on LPS-induced
microglial activation, we examined potential toxic effect
of paroxetine on BV2 microglial cells. The results
showed that cell viability was not different from the
control (0 μM) following the treatment of paroxetine
at 0.1, 0.2, 1 or 5 μM. The dose of 10 μM led to a
15.2% (P < 0.05) drop in cell viability compared with
the control (Figure 1), which was then excluded in
our following experiments.
To evaluate the impact of paroxetine on cytokine
production following LPS stimulation in BV2 cells, we
analyzed the release of two pro-inflammatory cytokines,
TNF-α and IL-1β, in the media. BV2 cells were treated
with LPS for 24 hours in the presence or absence of
paroxetine. Paroxetine alone did not elicit marked
alteration in the release of TNF-α or IL-1β, whereas
LPS stimulation significantly elevated the levels of
these two cytokines (Figure 2A). Pretreatment with
paroxetine led to a dose-dependent inhibition on
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paroxetine at 5 μM led to a significant (P < 0.05) reduction
by 68.3% and 85.3%, respectively, in TNF-α and IL-1β
generation at 24 hours post LPS stimulation (Figure 2A).
In order to understand the mechanism underlying the
inhibitory effect of paroxetine on LPS-induced cytokine
production, we analyzed the mRNA expression of TNF-α
and IL-1β following LPS stimulation. Consistent with
the cytokine release, LPS significantly up-regulated
mRNA expression of TNF-α and IL-1β at 24 hours,
which was in turn suppressed by 21.4% and 60.7%,
respectively, with 5 μM of paroxetine pretreatment
(Figure 2B). Paroxetine alone also slightly decreased
the basal mRNA level of TNF-α, whereas the basal
IL-1β level seems undetectable using our current PCR
program (Figure 2B).
Paroxetine suppresses LPS-induced NO production in
BV2 cells
To assess whether paroxetine has an impact on NO
release in microglial cells, we analyzed NO production
following LPS stimulation. BV2 cells were treated
with LPS for 24 hours in the presence or absence of
paroxetine. As shown in Figure 3A, paroxetine alone did
not lead to any change in NO production, whereas LPS
significantly induced the generation of NO in BV2 cells.
Pretreatment with paroxetine led to a dose-dependent
inhibition on LPS-induced NO production by 15.1% at 0.1
μM, 19.1% at 0.2 μM, 36.2% (P < 0.05) at 1 μM, and 59.1%
(P < 0.05) at 5 μM (Figure 3A). To understand the












Figure 4 Effect of paroxetine on lipopolysaccharide (LPS)-stimulated
with 5 μM paroxetine for 30 minutes followed by the treatment of LPS at 100
Western blot for the activation of p38, JNK1/2, ERK1/2 and p65/NF-κB. The lev
their respective total JNK1/2 or Erk1/2 levels. Each value was then expressed r
as 100. *P < 0.05 versus treated with LPS alone within the same time point. Va
LPS, lipopolysaccharide.inhibition on LPS-induced NO production, we analyzed
the expression of inducible nitric oxide synthase (iNOS)
following LPS stimulation. Paroxetine alone did not
change iNOS level, while LPS treatment significantly
up-regulated iNOS expression. In line with the changes
in NO production, pretreatment with paroxetine led
to a dose-dependent suppression on LPS-induced
iNOS expression by 2.9% at 0.1 μM, 12.0% at 0.2
μM, 28.4% (P < 0.05) at 1 μM, and 61.4% (P < 0.05) at
5 μM (Figure 3B).Paroxetine blocks LPS-induced JNK activation and attenuates
baseline ERK1/2 activity in BV2 cells
A number of studies have demonstrated that NF-κB and
MAPKs have important roles in modulating the expression
of pro-inflammatory cytokines and iNOS in LPS-stimulated
microglia [19,20]. Therefore, we investigated the effect of
paroxetine on the activity of p38, JNK, ERK1/2, and
p65/NF-κB in BV2 cells following LPS stimulation.
Paroxetine alone did not have any effect on the activation
of these kinases except ERK1/2 which displayed a drastic
drop (approximately 45%) in baseline phosphorylation
upon 5 μM of paroxetine treatment (Figure 4A and C).
Interestingly, LPS stimulation did not elicit activation of
ERK1/2 but indeed induced marked activation of JNK1/2,
p38, and p65/NF-κB in a time-dependent manner
(Figure 4A). The peak of activation for each kinase varied,
such as p38 peaked at 30 minutes post LPS stimulation,
JNK1/2 and p65 peaked at one hour. Pretreatment with


























































activation of MAPK and NF-κB in BV2 cells. Cells were pretreated
ng/mL for 0, 15, 30, 60 or 120 minutes. (A) Representative images of
els of p-JNK1/2 (B) and p-ERK1/2 (C) were quantified and normalized with
elative to the one treated with LPS alone for 60 minutes, which was set
lues are means ± SE of three independent experiments. PAR, paroxetine;
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http://www.jneuroinflammation.com/content/11/1/47JNK1/2 activation, but showed little influence on the
activation of p38 and p65 kinases (Figure 4A and B).
Paroxetine inhibits LPS-induced microglial activation
through JNK and ERK pathways
Since paroxetine inhibited LPS-induced JNK activation as
well as baseline ERK1/2 activity, we then asked whether the
inhibitory effect of paroxetine on microglial activation is via
JNK and (or) ERK pathways. We investigated the effect of
specific JNK inhibitor SP600125 and specific ERK1/2
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Figure 5 Inhibition of JNK or ERK signaling on lipopolysaccharide (LP
and U0126 on JNK1/2 and ERK1/2 activation. BV2 cells were treated with S
treatment (100 ng/mL) for one hour. (B) Measurement of NO production in
nitric oxide synthase (iNOS) expression (lower panel). Cells were pretreated
stimulation of LPS (100 ng/mL) for 24 hours. (C) The mRNA expression of T
(10 μM) for 30 minutes followed by stimulation of LPS (100 ng/mL) for six ho
with their respective β-actin. Each value was then expressed relative to the on
means ± SE of three independent experiments. SP, SP600125. LPS, lipopolysacinflammatory cytokines in BV2 cells. SP600125 and U0126
were firstly verified for their abilities to block JNK1/2 and
ERK1/2 activation, respectively, in BV2 cells (Figure 5A).
Pretreatment with SP600125 significantly suppressed
LPS-induced NO production by 82.3%. In contrast,
U0126 showed no effect on the NO production. In
line with the regulation on NO production, LPS-induced
iNOS expression was blocked by SP600125, but not by
U0126 (Figure 5B). On the other hand, both SP600125
and U0126 blunted LPS-induced cytokine up-regulation.
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S)-mediated microglia activation. (A) Inhibitory effect of SP600125
P600125 (20 μM) or U0126 (10 μM) for 30 minutes prior to LPS
culture media (upper panel) and Western blot analysis of inducible
with SP600125 (20 μM) or U0126 (10 μM) for 30 minutes followed by
NF-α and IL-1β. Cells were pretreated with SP600125 (20 μM) or U0126
urs. The mRNA levels of each cytokine were quantified and normalized
e treated with LPS alone, which was set as 100. *P < 0.05. Values are
charide.
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on LPS-induced TNF-α and IL-1β mRNA expression,
while U0126 reduced the elevation of these two cytokines
by 13.6% and 40.6% (P < 0.05), respectively (Figure 5C).
Similar to paroxetine, SP600125 and U0126 also
reduced the basal mRNA expression of TNF-α in BV2
cells (Figure 5C).
Paroxetine relieves microglia-mediated neurotoxicity
Microglia upon activation could induce neuronal cell
degeneration by releasing inflammatory mediators and
cytokines [6,21,22]. We therefore investigated whether
paroxetine contributes to the relief of activated microglia-
induced neurotoxicity. The neuroblastoma cell line
SH-SY5Y is often used in the cellular model of PD due to
its dopaminergic ability [23,24]. As shown in Figure 6,
conditioned media from LPS-stimulated, but not from
paroxetine alone-treated, BV2 cells significantly (P < 0.05)
increased cell death of SH-SY5Y cells. In contrast, the con-
ditioned media from BV2 cells pretreated with paroxetine
prior to LPS stimulation showed little neurotoxicity on
SH-SY5Y cells (Figure 6), suggesting that paroxetine
suppresses microglia-mediated neurotoxicity via reducing
the expression of inflammatory mediators.
Paroxetine suppresses LPS-stimulated pro-inflammatory
cytokines and NO in primary microglial cells
Primary microglial cells were isolated to repeat the
inhibitory effect of paroxetine on the cytokine and NO
production as observed in BV2 cells. Purity assessment
of the isolation displayed more than 98% of the cells
with positive staining (Figure 7A). We then evaluated



















Figure 6 Paroxetine relieves microglia-mediated neurotoxicity.
BV2 cells were first treated with lipopolysaccharide (LPS) (100 ng/mL)
for 24 hours with or without 30 minutes of paroxetine pretreatment at
5 μM. The media were then collected as condition media and added
to SH-SY5Y cells. After 24 hours incubation, cell viability of SH-SY5Y was
assessed and expressed as percentage of the control, which was set
as 100%. *P < 0.05. Values are means ± SE of three independent
experiments. PAR, paroxetine; LPS, lipopolysaccharide.microglial cells. Cell viability was not different from the
control (0 μM) following the treatment of paroxetine at
2.5, 5 or 7.5 μM, while the dose of 10 μM led to a 16.1%
(P < 0.05) decrease in cell viability (Figure 7B) and then
was excluded for the following experiments.
As expected LPS stimulation of primary microglial
cells led to a significant increase in cytokine release and
NO production after 24 hours. Pretreatment of primary
cells with paroxetine significantly inhibited the LPS-induced
TNF-α, IL-1β and NO productions in a dose-dependent
manner, while paroxetine alone did not apparently alter the
level of these mediators (Figure 7C and D). In particular,
paroxetine at 7.5 μM led to a significant (P < 0.05) reduction
by 45.7, 43.9 and 36.7%, respectively, in TNF-α, IL-1β and
NO productions at 24 hours post LPS stimulation. Further
analysis showed that the LPS-induced mRNA expression of
TNF-α and IL-1β at six hours was reduced by 14.4% and
23.3%, respectively, with 7.5 μM of paroxetine pretreatment
(Figure 7C). Similar to BV2 cells, paroxetine alone also
slightly decreased the basal mRNA level of TNF-α, whereas
the basal IL-1β level appeared under our detection limit.
LPS-stimulated iNOS expression was dose-dependently
attenuated by paroxetine with an inhibition of 36% at the
dose of 7.5 μM (Figure 7D).
Discussion
Microglia, an immune-like cell of the brain, plays an
important role in inflammatory responses in the central
nervous system. Activated microglia secrete large
amounts of neurotoxic factors, such as NO, TNF-α and
IL-1β. Recent studies have shown that these cytotoxic
factors play a critical role in the pathogenesis of brain
injury and neurodegenerative disorders such as PD and
Alzheimer’s disease [25], and also affect complex central
nervous system functions such as cognition, sleep and
depression [26-29]. Thus, inhibition of microglia
activation serves as a key mechanism in the treatment
of inflammation-associated neurological disorders. The
current study demonstrated an inhibitory role of par-
oxetine in microglia activation stimulated by LPS and
elucidated the underlying molecular mechanism, that
is, paroxetine suppresses LPS-induced NO produc-
tion via mediation of JNK1/2 activation, and inhibits
pro-inflammatory cytokines such as TNF-α and IL-1β
via collective regulation of JNK1/2 activation and
baseline ERK1/2 activity. Meanwhile, we observed
that paroxetine reduced BV2 microglia-mediated
neurotoxicity in line with the view that reduction of
microglia releasing excessive amount of neurotoxic
mediators is neuroprotective [30,31].
Paroxetine exhibited comparable inhibitory effects
on NO and cytokine productions in BV2 cell lines and
primary microglial cells. NO is generated from L-arginine
by three different isoforms of NOS, including endothelial
Iba-1 Hoechst 33258 MergeA
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Figure 7 Paroxetine suppresses the lipopolysaccharide (LPS)-stimulated pro-inflammatory cytokines and nitric oxide (NO) in primary
microglial cells. (A) Purity assessment of isolated primary microglial cells. Cells were immunostained with ani-Iba-1 antibody (red) and Hoechst
33258 for nuclei (blue). (B) Cell viability analysis. Cells were treated with 0, 2.5, 5, 7.5 or 10 μM of paroxetine for 24 hours. Cell viability was
expressed relative to the control (0 μM), which was set as 100%. Values are means ± SE of three independent experiments. *P < 0.05 versus the
control. (C) Effect of paroxetine on TNF-α and IL-1β productions. For cytokine release in media (the upper panel), cells were pretreated with par-
oxetine for 30 minutes and then stimulated with LPS at 100 ng/ml for 24 hours. *P < 0.05 versus treated with LPS alone. For mRNA expression
(the lower panel), cells were pretreated with 7.5 μM paroxetine for 30 minutes followed by LPS treatment at 100 ng/mL for six hours. The mRNA
levels of each cytokine were quantified and normalized with their respective β-actin. Each value was expressed relative to the one treated with
LPS alone, which was set as 100. *P < 0.05; values are means ± SE of four independent experiments. (D) Effect of paroxetine on NO production
(the upper panel) and inducible nitric oxide synthase (iNOS) expression (the lower panel). Cells were pretreated with paroxetine for 30 minutes
and then stimulated with LPS at 100 ng/ml for 24 hours. The iNOS protein levels were quantified and normalized with their respective β-actin.
Each value was expressed relative to the one treated with LPS alone, which was set as 100. *P < 0.05 versus treated with LPS alone. Values are
means ± SE of four independent experiments. PAR, paroxetine; LPS, lipopolysaccharide; NO, nitric oxide; iNOS, inducible nitric oxide synthase.
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occurs primarily in astrocytes and microglia in response
to extracellular stimuli including LPS, IL-1β, IFN-γ, and
TNF-α [33,34]. Excessive release of NO by activated
microglia leads to formation of peroxynitrite by reacting
with superoxide, which intoxicates cells by disturbing
mitochondrial respiration, reacting with cellular molecules
[35]. Our results showed that paroxetine suppressed the
LPS-elicited iNOS up-regulation in both types of cells
and thereby prevented the increase of NO production.
The basal NO level was not reduced by paroxetine
treatment, most likely due to the minimum baseline
iNOS expression. For cytokines, paroxetine markedly
inhibited LPS-induced elevation in both mRNA
expression and peptide release of TNF-α and IL-1β in
BV2 and primary microglial cells. Interestingly the
paroxetine-induced baseline change of TNF-α inpeptide release and mRNA expression appeared in a
discrepancy as the basal release of TNF-α in media
did not differ but its basal mRNA expression was to some
extent reduced by paroxetine, suggesting a differential re-
sponse of microglial TNF-α mRNA translating to the
release of peptide under normal and stressed (that is
with LPS stimulation) conditions. The situation is
unclear regarding IL-1β as its basal mRNA expression
was undetectable under our PCR condition. Tynan et
al. recently screened a set of antidepressants mainly
focusing on the comparison of immunomodulatory
effects between selective serotonin reuptake inhibitors
and serotonin-norepinephrine reuptake inhibitors, where
an inhibitory effect of paroxetine against LPS-stimulated
production of NO and TNF-α was also mentioned;
however, this was without further exploration on paroxetine
and associated signal wirings [36]. As far as drug dosage is
LPS
iNOS







Figure 8 Schematic illustration of paroxetine-mediated suppres-
sion of neuroinflammation. PAR, paroxetine; LPS, lipopolysaccharide;
NO, nitric oxide; iNOS, inducible nitric oxide synthase;➔, lead to/
activate;▬▌, inhibit.
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reaches a level between 0.19 and 0.32 μM in serum, and
the level of psychotropic drugs is usually detected 10
to 40 times higher in brain than in blood [37]. Therefore,
the 0.1 to 7.5 μM paroxetine used in this study is compar-
able to the putative level of therapeutic doses in brain, and
should be safe for other tissues when dosage is adminis-
tered therapeutically.
NF-κB and MAPK family including JNK, p38 and
ERK are key regulators involved in the production of
cytokines and mediators associated with the pathogenesis
of inflammatory processes [38-40]. Indeed, LPS induced
NF-κB activation as manifested by the phosphorylation of
p65 subunit, as well as p38 and JNK1/2 activation in BV2
cells. However, ERK1/2 activity was not elevated following
LPS stimulation as documented in several other studies
[41,42]. Pretreatment with paroxetine did not apparently
change LPS-induced p65 and p38 activation, demonstrat-
ing that the anti-inflammatory property of paroxetine does
not rely on NF-κB and p38 signaling. On the other hand,
baseline ERK1/2 activity and LPS-induced JNK1/2
activation were blunted by paroxetine pre-administration,
suggesting paroxetine-mediated anti-microglia activation
is potentially via inhibition of JNK1/2 and (or) ERK1/2
activities. These differential regulations indicate that
paroxetine preferentially targets the upstream of JNK and
ERK signaling. Unfortunately we cannot provide further
clues at this point due to the complexity and frequent
crosstalk in the MAPK network. Instead, we analyzed how
mediation of JNK and ERK signaling by paroxetine
contributes to the inhibition of microglia activation.
First, with regard to NO production, inhibition of JNK1/2
signaling by a specific inhibitor SP600125 led to nearly
complete abolishment of LPS-induced iNOS expression and
NO production, whereas inhibition of ERK1/2 signaling by
U0126 displayed no effect, suggesting iNOS expression is
induced mainly through JNK1/2 signaling. Indeed, suppres-
sion of iNOS induction and NO production in reactive
microglia by JNK1/2 inhibitors has been consistently re-
ported [43,44], while the role of ERK seems a bit controver-
sial as both inhibition and no impact by ERK1/2 inhibitors
have been reported [43,45]. Importantly, the data above
demonstrated that paroxetine-mediated suppression of NO
production is via mediation of JNK1/2 activation, but not
through ERK1/2 signaling. Compared with paroxetine,
SP600125 displayed a stronger inhibitory effect to iNOS ex-
pression and NO production, which is apparently due to
SP600125 being a more potent inhibitor for JNK1/2 activity.
As far as pro-inflammatory cytokines are concerned, both
inhibition of JNK1/2 by SP600125 and inhibition of ERK1/2
by U0126 resulted in a reduction of LPS-stimulated TNF-α
or IL-1β production. Data analysis showed that the reduc-
tion of LPS-elicited cytokine production by paroxetine
(21.4% and 60.7%, respectively for TNF-α and IL-1β) wassmaller than the sum (25.6% and 74.1%, respectively), but
larger than the individual values of the inhibition rates by
JNK1/2 inhibitor SP600125 (12.1% and 33.5%, respectively)
and ERK1/2 inhibitor U0126 (13.6% and 40.6%, respectively),
demonstrating that paroxetine suppresses LPS-induced cyto-
kine production collectively via JNK1/2 and ERK1/2 signal-
ing, but not likely through a single pathway. We also tried to
simultaneously block JNK1/2 and ERK1/2 activities to
further determine whether other pathways are involved in
the action of paroxetine. However, this effort was prevented
due to a sharp decrease in cell number following the addition
of both SP600125 and U0126 (data not shown), indicating
the presence of some activity from at least one of the path-
ways is required for the BV2 cell survival. On the other hand,
paroxetine-mediated inhibition of baseline cytokine
production seems solely via inhibition of ERK1/2 sig-
naling since ERK1/2 but not JNK1/2 baseline activity
was suppressed by paroxetine. Indeed, the inhibition rate of
basal TNF-α production with paroxetine (11.9%) did not
exceed that with U0126 (24.3%), a more potent ERK1/2
inhibitor. Interestingly, a fellow serotonin reuptake inhibi-
tor, fluoxetine, was also reported to inhibit LPS-mediated
microglia activation, but through regulation of NF-κB
and p38 activation [39], suggesting different signaling
mechanisms were involved in antidepressant mediated
anti-neuroinflammation.
Conclusions
In summary, the present study demonstrated the inhibitory
role of paroxetine in LPS-induced neuroinflammation and
dissected the underlying molecular mechanisms, that is,
paroxetine inhibits iNOS induction and NO generation by
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http://www.jneuroinflammation.com/content/11/1/47suppressing JNK1/2 activation, and attenuates cytokine
production by collectively inhibiting JNK1/2 activation and
baseline ERK1/2 activity (Figure 8). Since paroxetine
is originally set as an antidepressant, our results provide
further evidence to the point of view that depression
involves neuroinflammatory processes [36,46]. Given
the pathogenic role of inflammation in PD together
with the previous report showing paroxetine-mediated
prevention of neuronal degeneration in substantia nigra
[14], we cautiously suggest that paroxetine may possibly
be helpful in alleviating PD progression.
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